X-linked hypophosphatemia (XLH) and hypophosphotasia (HPP) are genetic metabolic bone diseases with recent treatment advances. This program will discuss when to refer and how to treat children with XLH or HPP in the era of disease specific therapies.

Join Dr. Amy Zack as she discusses diabetic retinopathy and emphasizes the need for eye health in patients with diabetes, how best to support patients for optimal eye health via education and screening, and Dr. Steven Ferrucci helps explain diabetic eye exams.

Are you up to date on the latest therapeutic targets for managing menopause-associated VMS?

This educational initiative intends to close β‑thalassemia clinical care gaps when transitioning patient care from pediatrics into adulthood

A physician and patient with obesity model a discussion on mitigating the patient’s risk for heart failure with strategies for weight loss and increased physical activity.

Identify the optimal CKD treatment option(s) based on patient clinical characteristics and benefits/risks of currently approved agents

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Identify barriers to diabetic eye care in vulnerable patient populations, such as older patients and racial and ethnic minorities
• Implement strategies that are proven to address disparities in diabetic eye care among underserved patient populations, including racial and ethnic minorities, and older patients

Upon completion of this activity, participants should be better able to:

• Describe the clinical burden of anemia in patients with CKD
• Discuss the pathophysiology of anemia in CKD, including therapeutic targets
• Apply current assessment strategies to accurately diagnose patients with anemia and CKD based on clinical presentation
• Develop appropriate therapeutic regimens for patients with anemia and CKD based on goals of therapy